AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00597363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neptune P.A.D. (R)
Description: The Neptune Pad ® (Biotronik GmbH \& Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
Study NCT00597363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional manual compression
Description: The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
Study NCT01151735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-1-esterase
Description: 1000 units of C-1-esterase inhibitor
Study NCT01151735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-1-esterase
Description: 1500 units of C-1-esterase inhibitor
Study NCT01151735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03738501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy with SET
Description: Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
Study NCT00827424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling by applying a modified PACE protocol
Description: Lifestyle counseling by applying a modified PACE protocol to obese Arab women
Study NCT02705495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Acupuncture will be performed according to the physiological concept of segmental acupuncture. A fixed schema of acupuncture points will be used irrespective of TCM diagnosis. Needles will be inserted approximately 10 mm under the skin. The deqi sensation (a sensation described as numbness, heaviness, and distension) may be obtained, but will not be specifically aimed for. The acupuncture protocol includes body and ear acupuncture.
Study NCT03738501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
Study NCT03738501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
Study NCT01317537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic personal health record
Study NCT03390478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Intervention Group
Description: Experimental: Combined Intervention Program is composed by a Cognitive Stimulation Program (CSP), a Physical Activity Program (PAP) and Animal Assisted Therapy (AAT). During the PAP participants that use rolling-walkers, will do PAP using the Auto-Blocking kit mechanism for rolling walkers (ABMRW).
Study NCT01259076 — intervention group
Intervention type: PROCEDURE
Intervention: magnetic resonance imaging
Description: Undergo MRI at baseline and 1 year later.
Study NCT02705495 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cranberry products
Description: Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
Study NCT02705495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry products
Description: Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
Study NCT02508402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using
Study NCT02508402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two milliliters of normal saline given to placebo group .
Study NCT02835807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Chat including Indoor Tanning
Description: Participants in the intervention join a private Facebook group to participate in the Health Chat program. The group is not viewable to the public, including other Facebook users. The content of Health Chat is designed primarily for mothers, the participants in the group. Posts will occur twice daily for 12 months for a total of 720 posts. Each group will be hosted by a moderator who is responsible for managing the intervention goals and mothers' engagement. Mothers likely will not continuously engage with a social media campaign that is limited only to indoor tanning. To engage mothers in the Health Chat program, content addressing several major health and wellness topics relevant to adolescent girls and their mothers will be posted.
Study NCT02835807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Chat excluding Indoor Tanning
Description: In the comparison condition, 25% of the posts will be about prescription drug abuse and misuse. Prescription drug abuse was selected as control content because it is a) completely unrelated to tanning, and b) an emerging issue of great interest and relevance to young adults in east Tennessee. This 25% segment of posts is the only difference between the intervention and comparison conditions.
Study NCT03552653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitafusion Extra Strength Vitamin D
Description: Monitor Vitamin D blood levels
Study NCT03552653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitafusion Extra Strength Vitamin D
Description: Monitor Vitamin D blood levels
Study NCT01409564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
Study NCT01409564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
Study NCT01413191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: 10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks
Study NCT01413191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study NCT01280916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body-oriented Therapy
Description: 8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
Study NCT00846131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Randomized to Y-90 ± Sorafenib
Study NCT00846131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yttrium-90 (Y-90)
Description: Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
Study NCT00846131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y-90)
Description: Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
Study NCT00280462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (drug)
Description: Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
Study NCT00280462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine (drug)
Description: Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
Study NCT00280462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginin (drug)
Description: L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
Study NCT00280462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Arginin (drug)
Description: L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
Study NCT00280462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00280462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01036035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Comparison of different dosages of drug
Study NCT01259076 — intervention group
Intervention type: PROCEDURE
Intervention: digital mammography
Description: Undergo digital mammography at baseline and 1 year later.
Study NCT01259076 — intervention group
Intervention type: PROCEDURE
Intervention: conventional surgery
Description: Undergo gastric bypass surgery
Study NCT02446418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
Study NCT02446418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
Study NCT02446418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
Study NCT02446418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
Study NCT02446418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
Study NCT02446418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
Study NCT01716338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Study NCT01716338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01036035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine
Description: Comparison of different dosages of drug
Study NCT04080479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quadriceps Muscle Layer Fitness
Description: The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
Study NCT04080479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle Strength
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.
Study NCT04080479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acute Physiology and Chronic Health Evaluation
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
Study NCT04080479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
Study NCT04080479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nutritional Risk Screening
Description: All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
Study NCT04080479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Energy and Protein Intake
Description: The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
Study NCT01420874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
Study NCT01420874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRBi armed ATC Infusions
Description: Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
Study NCT04120857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Stretching
Description: 60 minutes fo gentle stretching twice weekly for 8 weeks
Study NCT01893879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for study drug
Description: Given PO
Study NCT02281487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy plus Tubectomy
Description: hysterectomy with tubectomy
Study NCT02281487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: standard hysterectomy
Study NCT02281487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light microscopy
Description: analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
Study NCT01463930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational audiovisual videodisc and medical verbal information
Description: General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
Study NCT01463930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical verbal information
Description: General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
Study NCT03135444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSA TOOL
Description: Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.
Study NCT03135444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revised PSA TOOL
Description: Patients will be given the revised PSA TOOL, after providers have given their initial feedback.
Study NCT03135444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informal Interview
Description: Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
Study NCT01036035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THVD-201
Description: Comparison of different dosages of drug
Study NCT01036035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Comparison of different dosages of drug
Study NCT04876625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myTAP oral appliance plus mouth shield
Description: myTAP anti-snoring oral appliance worn with mouth shield for all 8-weeks; the mouth shield is a comfort accessory that fits over the oral appliance itself and extends into the oral vestibule.
Study NCT04876625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: myTAP oral appliance alone for first 4 weeks
Description: myTAP anti-snoring oral appliance worn alone for first 4 weeks followed by wearing it for 4 weeks with the mouth shield
Study NCT04234581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysulin
Description: Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.
Study NCT04234581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lysulin
Description: Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.
Study NCT01027221 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant photon radiation
Description: single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
Study NCT01390779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Description: Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
Study NCT04046354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Percutaneous Microwave Ablation
Description: Ultrasound-guided Percutaneous Microwave Ablation
Study NCT04046354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Percutaneous Radiofrequency Ablation
Description: Ultrasound-guided Percutaneous Radiofrequency Ablation
Study NCT01893879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (RS)2-(3-benzoylphenyl)-propionic acid
Description: Given PO
Study NCT01893879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01893879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02865681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menopur
Description: Nasal versus injectable
Study NCT02865681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menopur
Description: Nasal versus injectable
Study NCT02865681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synarel
Description: nasal
Study NCT02937298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Meal
Description: This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
Study NCT02937298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry Treatment
Description: This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
Study NCT02865681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synarel
Description: nasal
Study NCT02865681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG trigger
Description: injectable
Study NCT02865681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: oral
Study NCT02865681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Description: oral
Study NCT02865681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Oral
Study NCT02865681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Oral
Study NCT02937298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea Buckthorn Treatment
Description: This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
Study NCT02937298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Garlic Treatment
Description: This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
Study NCT01027221 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant photon radiation
Description: single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
Study NCT01027221 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant photon radiation
Description: single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection